← Map · Health Care Equipment · S&P MidCap 400
LIVN LIVANOVA PLC $4.1B
No. AI is inside the R&D sentence, not a named product.
4 of 15
Reach, Weight, and Proof.
What they are doing
LivaNova's annual report lists AI inside research and development spend, next to software and clinical studies, and says incorporating AI is necessary to stay competitive. It also says success depends on the ability to integrate it. There is no named AI product in epilepsy or cardiopulmonary. The other AI sentences are about attackers using it, and about rivals who might.
Why the score
- Reach 1 not 2: named inside R&D spend. Not a function we can see running.
- Weight 1 not 2: necessary and ability to integrate is not hygiene in production.
- Proof 2 not 3: named in the annual report and tied to R&D. No program in the loop.
What would move it next quarter: A named intelligence layer in a LivaNova therapy. Another R&D sentence will not move this.
Open these first
Evidence
R&D investment consists of product design and development expenses, including technology, AI, software, clinical study programs, and regulatory activities. Product improvement, incorporation of AI, and software advancements are described as necessary to maintain market leadership. Success depends in part on the ability to integrate advanced software and AI capabilities.